Stock of the Day

CRISPR Therapeutics (CRSP)

$47.91

-$2.52 (-5.0%)

Market Cap: $4.33B

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA.

CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Recent News

• Samarth Kulkarni Sells 18,360 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock (insidertrades.com)
• CRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy Now (msn.com)
• Market Whales and Their Recent Bets on CRSP Options (benzinga.com)
• CRISPR set to snap six days of gains as shares trade in red (msn.com)
• Citi Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP) (markets.businessinsider.com)
• Crispr Therapeutics price target lowered to $82 from $89 at Citi (markets.businessinsider.com)
• Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI (markets.businessinsider.com)